VP-128, a novel oestradiol-platinum(II) hybrid with selective anti-tumour activity towards hormone-dependent breast cancer cells in vivo

Endocrine-Related Cancer

Volumn 16, Issue 4, 2009, Pages 1185-1195

  Van Themsche, Céline ^a   Parent, Sophie ^a   Leblanc, Valérie ^a   Descôteaux, Caroline ^a   Simard, Anne Marie ^a   Bérubé, Gervais ^a   Asselin, Eric ^a  

^a UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; CASPASE 3; CASPASE 9; CISPLATIN; ESTROGEN RECEPTOR ALPHA; MYC PROTEIN; PLATINUM COMPLEX; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN KINASE B; UNCLASSIFIED DRUG; VP 128; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CHROMATIN CONDENSATION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG DOSE INCREASE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SIDE EFFECT; WEIGHT REDUCTION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASE 3; CELL PROLIFERATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; ORGANOPLATINUM COMPOUNDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBCELLULAR FRACTIONS; TUMOR CELLS, CULTURED; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 72549095564     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0113     Document Type: Article

References (42)

1. Asselin E, Mills GB & Tsang BK 2001 XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Research 61 1862-1868. (Pubitemid 32692000)
2. Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G, Godwin AK, Hibshoosh H, Hopper JL et al. 2007 BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. American Journal of Surgical Pathology 31 121-128. (Pubitemid 46036911)
3. Betsch B 1990 The pharmacokinetic model and distribution pattern of new sexual-steroid-hormone-linked anticancer agents. Journal of Cancer Research and Clinical Oncology 116 467-469. (Pubitemid 20359906)
4. Blanc C, Deveraux QL, Krajewski S, Janicke RU, Porter AG, Reed JC, Jaggi R & Marti A 2000 Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Research 60 4386-4390. (Pubitemid 32103616)
5. Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM & Thompson EW 2008 Epithelial-mesenchymal transition traits in human breast cancer cell lines. Clinical & Experimental Metastasis 25 629-642.
6. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd OA, Menke-Pluymers MB, Bartels CC, Kriege M, van Geel AN, Burger CW, Eggermont AM et al. 2007 Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. European Journal of Cancer 43 867-876.
7. Clarke R, Leonessa F, Welch JN & Skaar TC 2001 Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacological Reviews 53 25-71. (Pubitemid 32173107)
8. Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, Ormiston W, Daly PA, Ford D, Easton DF et al. 1995 Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 10 1673-1675.
9. Dauvois S, White R & Parker MG 1993 The antiestrogen ICI 182 780 disrupts estrogen receptor nucleocytoplasmic shuttling. Journal of Cell Science 106 1377-1388. (Pubitemid 24018422)
10. Descoteaux C, Leblanc V, Belanger G, Parent S, Asselin E & Berube G 2008 Improved synthesis of unique estradiol-linked platinum(II) complexes showing potent cytocidal activity and affinity for the estrogen receptor alpha and beta. Steroids 73 1077-1089.
11. Dubik D & Shiu RP 1992 Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7 1587-1594.
12. Euhus DM, Hudd C, LaRegina MC & Johnson FE 1986 Tumor measurement in the nude mouse. Journal of Surgical Oncology 31 229-234.
13. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL & Cronin WM 1994 Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. Journal of the National Cancer Institute 86 527-537. (Pubitemid 24111008)
14. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG et al. 2005 Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 97 1652-1662. (Pubitemid 41672231)
15. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N et al. 1989 Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1 117-120. (Pubitemid 19034031)
16. Gagnon V, Van Themsche C, Turner S, Leblanc V & Asselin E 2008 Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 13 259-271.
17. Havelka AM, Berndtsson M, Olofsson MH, Shoshan MC & Linder S 2007 Mechanisms of action of DNA-damaging anticancer drugs in treatment of carcinomas: is acute apoptosis an "off-target" effect? Mini Reviews in Medicinal Chemistry 7 1035-1039.
18. He Q, Liang CH & Lippard SJ 2000 Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. PNAS 97 5768-5772. (Pubitemid 30367473)
19. Hubert A, Mali B, Hamburger T, Rottenberg Y, Uziely B, Peretz T & Kadouri L 2009 Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer. Familial Cancer 8 173-177.
20. Jordan VC & O'Malley BW 2007 Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. Journal of Clinical Oncology 25 5815-5824.
21. Kelland L 2007 The resurgence of platinum-based cancer chemotherapy. Nature Reviews. Cancer 7 573-584.
22. Kuwahara D, Tsutsumi K, Kobayashi T, Hasunuma T & Nishioka K 2000 Caspase-9 regulates cisplatin-induced apoptosis in human head and neck squamous cell carcinoma cells. Cancer Letters 148 65-71. (Pubitemid 30012130)
23. Lee YR, Park J, Yu HN, Kim JS, Youn HJ & Jung SH 2005 Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. Biochemical and Biophysical Research Communications 336 1221-1226. (Pubitemid 41383452)
24. Lee MW, Kim DS, Min NY & Kim HT 2008 Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin. International Journal of Cancer 122 2380-2384.
25. Loose-Mitchell DS, Chiappetta C & Stancel GM 1988 Estrogen regulation of c-fos messenger ribonucleic acid. Molecular Endocrinology 2 946-951. (Pubitemid 18236811)
26. MacGregor JI & Jordan VC 1998 Basic guide to the mechanisms of antiestrogen action. Pharmacological Reviews 50 151-196.
27. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D & Ando S 2004 The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. Journal of Biological Chemistry 279 27008-27016. (Pubitemid 38812536)
28. Muggia FM & Fojo T 2004 Platinums: extending their therapeutic spectrum. Journal of Chemotherapy 16 77-82. (Pubitemid 40065289)
29. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F et al. 2006 A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10 515-527. (Pubitemid 44854747)
30. Nunez AM, Jakowlev S, Briand JP, Gaire M, Krust A, Rio MC & Chambon P 1987 Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7. Endocrinology 121 1759-1765. (Pubitemid 18012781)
31. Ott I & Gust R 2007 Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Anti-Cancer Agents in Medicinal Chemistry 7 95-110. (Pubitemid 46062407)
32. Otto AM, Faderl M & Schonenberger H 1991 Dissociation of estrogenic and cytotoxic properties of an estrogen receptor-binding platinum complex in human breast cancer cell lines. Cancer Research 51 3217-3223.
33. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL & Leitman DC 2004 Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Research 64 423-428. (Pubitemid 38114127)
34. Perron V, Rabouin D, Asselin E, Parent S, Gaudreault R & Berube G 2005 Synthesis of 17beta-estradiol-linked platinum(II) complexes and their cytocidal activity on estrogen-dependent and -independent breast tumor cells. Bioorganic Chemistry 33 1-15. (Pubitemid 40164182)
35. Piccart MJ, Lamb H & Vermorken JB 2001 Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Annals of Oncology 12 1195-1203. (Pubitemid 32994741)
36. Sharma U, Marquis JC, Nicole DA, Hillier SM, Fedeles B, Rye PT, Essigmann JM & Croy RG 2004 Design, synthesis, and evaluation of estradiol-linked genotoxicants as anti-cancer agents. Bioorganic & Medicinal Chemistry Letters 14 3829-3833. (Pubitemid 38765173)
37. Sommer S & Fuqua SA 2001 Estrogen receptor and breast cancer. Seminars in Cancer Biology 11 339-352.
38. Susin SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loeffler M, Costantini P, Ferri KF, Irinopoulou T, Prevost MC et al. 2000 Two distinct pathways leading to nuclear apoptosis. Journal of Experimental Medicine 192 571-580.
39. Van Themsche C, Mathieu I, Parent S & Asselin E 2007 Transforming growth factor-beta3 increases the invasiveness of endometrial carcinoma cells through phosphatidylinositol 3-kinase-dependent up-regulation of X-linked inhibitor of apoptosis and protein kinase c-dependent induction of matrix metalloproteinase-9. Journal of Biological Chemistry 282 4794-4802. (Pubitemid 47100989)
40. Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC & Ashworth A 2005 Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harbor Symposia on Quantitative Biology 70 139-148. (Pubitemid 44124865)
41. Wang D & Lippard SJ 2005 Cellular processing of platinum anticancer drugs. Nature Reviews. Drug Discovery 4 307-320. (Pubitemid 41130944)
42. Zeng Q, Chen G, Vlantis A, Tse G & van Hasselt C 2008 The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas. Journal of Pathology 214 425-433. (Pubitemid 351350536)